Subjects must be capable of providing signed and dated written informed consent by date of Visit 0 (-2 week).
Male and female aged =19 and < 65 years.
Subjects diagnosed of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria, and a history of illness for at least for 3 years prior to screening.
Subjects who take atypical antipsychotic drugs, and should be maintained on current antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening.
Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to long-acting injectable aripiprazole in the investigator's judgement.
Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures.

NCT03376763_inc_T2
Person
Male
NCT03376763_inc_T3
Person
female
NCT03376763_inc_T4
Person
aged
NCT03376763_inc_T5
Value
=19 and < 65 years
NCT03376763_inc_T6
Condition
schizophrenia
NCT03376763_inc_T7
Qualifier
Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria
NCT03376763_inc_T8
Observation
history of illness
NCT03376763_inc_T9
Multiplier
for at least for 3 years
NCT03376763_inc_T10
Temporal
prior to screening
NCT03376763_inc_T11
Drug
atypical antipsychotic drugs